Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2NET 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

atezolizumab 2Magnetic Resonance Spectroscopy 2tivozanib 1romidepsin 1pembrolizumab 1pasireotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1Specimen Handling 1Respiratory Therapy 1Quality of Life 1Patient Reported Outcome Measures 1PT-100 dipeptide 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Lactones 1Immunotherapy 1Fluorodeoxyglucose F18 1FAPI-46 1Drug Therapy 1Depsipeptides 1Cabergoline 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × gadolinium ethoxybenzyl DTPA × NET × Clear all
NCT04373564 2026-01-22

ODYSSEY

Guerbet

Phase 4 Recruiting
2,076 enrolled
BreastEndocrineGastrointestinalGenitourinaryNET

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡